Effectiveness of the vaccines against SARS-CoV-2 used in Spain: infection, hospitalization and mortality in people aged fifty to fifty-nine years

In this paper we compared brand-specific COVID-19 vaccine effectiveness (VE) during August 2021 in persons born 1962-1971 and vaccinated during June. For SARS-CoV-2 symptomatic infection, protection was lower for Janssen (56%;CI95%: 53-59) or AstraZeneca [Vaxzevria] (68%;CI95%: 65-70), compared to Pfizer-BioNTech [Comirnaty] (78%;CI95%: 77-78), AstraZeneca/Pfizer (86%;CI95%: 80-90) or Moderna [Spikevax] (89%;CI95%: 88-90). VE against hospitalization was ranged 86% for Janssen to 97%-98% for other vaccines.

Brand-specific vaccine effectiveness against SARS-CoV-2 infection, hospitalization and mortality, in people aged 50-59 years in Spain

We compared brand-specific vaccine effectiveness during August 2021 in people born between 1962 and 1971, vaccinated during June. For symptomatic infection, protection was lower for Janssen (56%;53-59) or Astra Zeneca (68%;65-70), compared to Pfizer (78%;77- 78), AZ/Pfizer (86%;80-90) or Moderna (89%;88-90). VE against hospitalization ranged 86% for Janssen to 97-98% for other vaccines.